Literature DB >> 8757502

Interaction of the receptor tyrosine kinase p145c-kit with the p210bcr/abl kinase in myeloid cells.

M Hallek1, S Danhauser-Riedl, R Herbst, M Warmuth, A Winkler, H J Kolb, B Druker, J D Griffin, B Emmerich, A Ullrich.   

Abstract

The chimaeric bcr/abl oncogene is detected in virtually all cases of chronic myelogenous leukaemia (CML). It encodes a constitutively active tyrosine kinase of 210 kDalton, p210bcr/abl, which stimulates a variety of cytosolic signalling intermediates. The effects of bcr/abl on the activity of growth factor receptors are less well known. In order to investigate interaction of p210bcr/abl with the receptor tyrosine kinase p145c-kit, we used two myeloid, factor-dependent cell lines, MO7 and 32D, to generate bcr/abl positive sublines, MO7p210 and 32Dp210, by transfection with the bcr/abl gene. Since 32D and 32Dp210 cells did not express p145c-kit, a c-kit retrovirus was used to generate c-kit positive cell lines (32Dkit, 32Dp210kit). In contrast to MO7 and 32Dkit cells, MO7p210 and 32Dp210kit cells were factor independent and did not respond to the growth-promoting effects of recombinant human Steel factor (rhSF). Preincubation with a monoclonal antibody (MAb) neutralizing the binding of SF to p145c-kit did not affect the growth of MO7p210 cells, thus eliminating the possibility of an autocrine SF secretion. 32Dkit cells transfected with bcr/abl containing an inactivating point mutation (Lys-->Arg271) in the Abl kinase domain (32Dp210(Arg271)kit) retained their responsiveness to the effects of rhSF. Immune complex kinase assays showed that the kinase activity of p145c-kit was several-fold higher in MO7p210 and 32Dp210kit cells than in MO7, 32Dkit and 32Dp210(Arg271)kit cells, suggesting that Abl kinase activity was necessary to activate p145c-kit. Co-immunoprecipitation experiments with anti-Kit and anti-Abl MAbs demonstrated that p145c-kit and p210bcr/abl were associated in an intracellular complex in human bcr/abl positive, c-kit positive cell lines (MO7p210; GM/SO). Finally, colony assays with bone marrow from bcr/abl positive CML patients showed that the haemopoietic progenitors of three of four patients did not respond to rhSF. Taken together, the results suggest that p145c-kit can be activated by p210bcr/abl via an Abl-kinase dependent mechanism involving the complex formation of both proteins. These findings could explain some clinical features (basophilia, increase of immature myeloid cells) of chronic-phase CML.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8757502     DOI: 10.1046/j.1365-2141.1996.6102053.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  8 in total

1.  KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors.

Authors:  Amie S Corbin; Thomas O'Hare; Zhimin Gu; Ira L Kraft; Anna M Eiring; Jamshid S Khorashad; Anthony D Pomicter; Tian Y Zhang; Christopher A Eide; Paul W Manley; Jorge E Cortes; Brian J Druker; Michael W Deininger
Journal:  Cancer Res       Date:  2013-07-25       Impact factor: 12.701

2.  Pathological interactions between hematopoietic stem cells and their niche revealed by mouse models of primary myelofibrosis.

Authors:  Lilian Varricchio; Annalisa Mancini; Anna Rita Migliaccio
Journal:  Expert Rev Hematol       Date:  2009-06-01       Impact factor: 2.929

3.  Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations.

Authors:  S Wong; J McLaughlin; D Cheng; C Zhang; K M Shokat; O N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-25       Impact factor: 11.205

4.  The TEL/ARG leukemia oncogene promotes viability and hyperresponsiveness to hematopoietic growth factors.

Authors:  Keiko Okuda; Yuko Sato; Yoshiaki Sonoda; James D Griffin
Journal:  Int J Hematol       Date:  2004-02       Impact factor: 2.490

5.  Modeling of molecular interaction between apoptin, BCR-Abl and CrkL--an alternative approach to conventional rational drug design.

Authors:  Soumya Panigrahi; Jörg Stetefeld; Jaganmohan R Jangamreddy; Soma Mandal; Sanat K Mandal; Marek Los
Journal:  PLoS One       Date:  2012-01-10       Impact factor: 3.240

6.  Crosstalk between BCR/ABL oncoprotein and CXCR4 signaling through a Src family kinase in human leukemia cells.

Authors:  Andrzej Ptasznik; Elzbieta Urbanowska; Suneetha Chinta; Melinda A Costa; Benjamin A Katz; Marisha A Stanislaus; Gokhan Demir; Diana Linnekin; Zhixing K Pan; Alan M Gewirtz
Journal:  J Exp Med       Date:  2002-09-02       Impact factor: 14.307

7.  PI3K/mTOR pathway inhibitors sensitize chronic myeloid leukemia stem cells to nilotinib and restore the response of progenitors to nilotinib in the presence of stem cell factor.

Authors:  K Airiau; F-X Mahon; M Josselin; M Jeanneteau; F Belloc
Journal:  Cell Death Dis       Date:  2013-10-03       Impact factor: 8.469

8.  Mapping of apoptin-interaction with BCR-ABL1, and development of apoptin-based targeted therapy.

Authors:  Jaganmohan R Jangamreddy; Soumya Panigrahi; Kourosh Lotfi; Manisha Yadav; Subbareddy Maddika; Anil Kumar Tripathi; Sabyasachi Sanyal; Marek J Łos
Journal:  Oncotarget       Date:  2014-08-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.